Invivogen
Menu

Anti-hIL6R (Tocilizumab) mAbs

Anti-hIL6R-To-hIgG1 Unit size Cat. code Docs Qty Price
Recombinant monoclonal human IgG1 antibody against IL-6R (Tocilizumab)
100 µg
hil6rto-mab1
+-
$336.00
Anti-hIL6R-To-hIgG1NQ Unit size Cat. code Docs Qty Price
Recombinant monoclonal human IgG1NQ antibody against IL-6R (Tocilizumab)
100 µg
hil6rto-mab12
+-
$336.00
Anti-hIL6R-To-hIgA2 Unit size Cat. code Docs Qty Price
Recombinant monoclonal human IgA2 antibody against IL-6R (Tocilizumab)
100 µg
hil6rto-mab7
+-
$336.00

Recombinant anti-hIL-6R antibody (Tocilizumab)

Tocilizumab blocks IL-6R signaling
Tocilizumab blocks IL-6R signaling

InvivoGen provides a family of Anti-hIL6R-derived monoclonal antibodies (mAbs) in multiple human isotypes. These mAbs feature:

  • the variable region of Tocilizumab, which specifically targets the human interleukin-6 receptor (hIL6R)
  • constant region that mediates different effector functions depending on the isotype: hIgG1, hIgG1NQ or IgA2

InvivoGen's hIL6R mAbs have been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography.

IL-6R background

Tocilizumab (TCZ) is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. TCZ exhibits anti-inflammatory activity by inhibiting the binding of the pro-inflammatory cytokine, IL-6  to its receptor [1]. IL-6 exerts its biological effects through IL-6R, and the transmembrane protein gp130. Despite only a few cells expressing IL-6R on their surface, many cells respond to IL-6 due to the existence of soluble IL-6R [2]. TCZ can block both modes of signaling [1]. TCZ has been approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome (CRS), a side effect of CAR-T therapy. Furthermore, it is under investigation for the treatment of the late-stage hyperinflammation observed in severe COVID‑19 patients [3].

 

Key features of the Anti-hIL6R isotype family:

  • Clinically-relevant variable region targeting human IL-6R (Tocilizumab).
  • Inhibition of IL-6-dependent signaling by Anti-hIL6R-To mAbs has been validated in HEK-Blue™ IL-6 cellular assays.
  • The absence of bacterial contamination has been confirmed.

 

InvivoGen’s products are for research use only, and not for clinical or veterinary use.

 

 

COVID-19 related research

Severe COVID-19 patients have been shown to exhibit high levels of pro-inflammatory cytokines, such as IL-6, which can ultimately initiate life-threatening hyper-inflammation and a “cytokine storm” in the lungs and other organs. Tocilizumab is being explored as a potential therapeutic in the treatment of these patients.

 

Learn more on SARS-CoV-2Read our reviews on COVID-19 and learn more about SARS-CoV-2 infection cycle, immune responses, and potential therapeutics.

 

References:

1. Sheppard, M. et al. 2017. Tocilizumab (Actemra). Hum Vaccin Immunother 13, 1972- 1988.
2. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8, 1237-1247.
3. Zhang, S. et al. 2020. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig.

Figures


For your research, InvivoGen provides an Anti-hIL6R-To isotype family. This collection consists of mAbs comprising the variable region of Tocilizumab and differing constant regions of both native and engineered human isotypes. The isotypes differ in their effector functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody‑dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). The Anti‑hIL6R-To isotype family will help you determine which isotype is the most suitable for your application.

Inhibition of IL-6R signaling by Anti-hIL6R-To-hIgG1
Inhibition of IL-6R signaling by Anti-hIL6R-To-hIgG1

Dose-dependent inhibition of HEK-Blue™ IL-6 cellular response. Anti-hIL6R-To-hIgG1 (0 - 1 μg/ml) was incubated with HEK-Blue™ IL-6 cells for 3 hours. Following this, human (h)IL-6 (0.3 ng/ml) was added to the cells. After overnight incubation, STAT3‑dependent SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution, a SEAP detection reagent. Data are presented as percentage (%) of the maximum response.

Inhibition of IL-6R signaling by Anti-hIL6R-To-hIgG1NQ
Inhibition of IL-6R signaling by Anti-hIL6R-To-hIgG1NQ

Dose-dependent inhibition of HEK-Blue™ IL-6 cellular response. Anti-hIL6R‑To‑hIgG1NQ (0 - 1 μg/ml) was incubated with HEK-Blue™ IL-6 cells for 3 hours. Following this, human (h)IL-6 (0.3 ng/ml) was added to the cells. After overnight incubation, STAT3‑dependent SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution, a SEAP detection reagent. Data are presented as percentage (%) of the maximum response.

Inhibition of IL-6R signaling by Anti-hIL6R-To-hIgA2
Inhibition of IL-6R signaling by Anti-hIL6R-To-hIgA2

Dose-dependent inhibition of HEK-Blue™ IL-6 cellular response. Anti-hIL6R‑To‑hIgA2 (0 - 1 μg/ml) was incubated with HEK-Blue™ IL-6 cells for 3 hours. Following this, human (h)IL-6 (0.3 ng/ml) was added to the cells. After overnight incubation, STAT3‑dependent SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution, a SEAP detection reagent. Data are presented as percentage (%) of the maximum response.

Back to the top

Specifications

Specificity: Human Interleukin-6 receptor (hIL-6R)
Clonality: Monoclonal antibodies
Source: CHO cells
Formulation: 0.2 μm filtered solution in a sodium phosphate buffer with glycine, saccharose, and stabilizing agents.
Purification: 

  • hIgG1: purified by affinity chromatography with protein G
  • hIgG1NQ: purified by affinity chromatography with protein G
  • hIgA2: purified by affinity chromatography with peptide M

Quality control:

  • The complete sequence of each antibody construct has been verified.
  • Each antibody has been functionally validated using HEK-Blue™ IL-6 cellular assays
  • The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cellular assays.
Back to the top

Contents

  • 100 µg purified antibody, azide-free, and lyophilized

room temperature The product is shipped at room temperature.

store Store lyophilized antibody at -20 °C.

stability Lyophilized product is stable for at least 1 year.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty